Abstract 5000: Biomaterial scaffolds that capture metastatic tumor cells in vivo to detect, treat, and study mechanisms of the premetastatic niche and metastasis

Abstract

Objective: For most cancers, the formation of distant metastasis is the point at which clinical treatment shifts from curative intent to palliative care. At present, there is no clinical method to detect metastatic dissemination and colonization until radiologically evident, at which point organ function has already been compromised. The Shea laboratory has developed a biomaterial implant that acts as a synthetic pre-metastatic niche and recruits metastatic cancer cells in xenogeneic human and syngeneic mouse models of breast cancer. Scaffold implantation has facilitated detection of metastasis prior to colonization of organs and has been shown to reduce metastatic burden, resulting in enhanced survival with surgical intervention. Methods: Triple-negative breast cancer models were used in which tdTomato+ 4T1 or MDA-MB-231-BR cells were orthotopically inoculated into balb/c or NSG mice. Microporous polycaprolactone (PCL) scaffolds were fabricated using gas-foaming and poragen leaching and were subcutaneously implanted one month prior to tumor inoculation. High frequency ultrasound (US) was used to probe the scaffold for early detection of tumor cells prior to metastasis to organs. Human tumor cells were isolated from the scaffold (SCAF), primary tumor (PT), and a bone metastasis via MACS mouse cell depletion (Miltenyi) and grown into stable cell lines in vitro. Scratch, migration, invasion, mammosphere, cancer stem cell markers, RNA-seq, qRT-PCR, and HiC assays were performed to investigate behavioral differences between cell lines in vitro. Additionally, cell lines were inoculated into mice and investigated for metastatic ability. Results: Initial studies applied US for detection of metastatic cell arrival at the scaffold. The analysis of spectral imaging distinguished scaffolds from tumor bearing relative to tumor free mice. A cell line created from the scaffold (SCAF) was more aggressive in vitro, demonstrating higher levels of migration, invasion, mammosphere formation, and proportion of cancer stem cells compared to PT. SCAF cells were also found to be ~30x more metastatic to the lung in vivo compared to PT cells (SCAF 10,150±7792 PT 354±296 cells per lung). RNA-seq identified 14232 genes with measured expression, 2901 of which were differentially expressed (p<0.05 and log fold change > 0.6) between scaffold and primary tumor cells. Conclusions: Biomaterial scaffolds capable of recruiting metastatic tumor cells in vivo can serve as a platform for early detection and intervention, and also provide a tool to study metastasis in vivo and the properties of the early metastatic cells. Citation Format: Grace G. Bushnell, Tejaswini P. Hardas, Rachel M. Hartfield, Yining Zhang, Robert S. Oakes, Adeline Hong, Jacqueline S. Jeruss, Lonnie D. Shea. Biomaterial scaffolds that capture metastatic tumor cells in vivo to detect, treat, and study mechanisms of the premetastatic niche and metastasis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5000.

Engineered immunologic niche monitors checkpoint blockade response and probes mechanisms of resistance

“…The biopsy of metastatic sites has been proposed as having the appropriate characteristics, yet the biopsy of a vital organ, such as the lung, has associated risks and cannot be routinely performed for biomarker assessment. We have previously reported an implant that supports the formation of a surrogate tissue in the subcutaneous space, which recruits tumor cells, 39–41 and the immune cells within this engineered tissue are characteristic of those within an inflamed vital organ such as the metastatic lung 42 . A microporous scaffold is implanted subcutaneously, with the porous structure supporting persistent intravasation of host cells and vascularization.…”

“…We have previously reported an implant that supports the formation of a surrogate tissue in the subcutaneous space, which recruits tumor cells, [39][40][41] and the immune cells within this engineered tissue are characteristic of those within an inflamed vital organ such as the metastatic lung. 42 A microporous scaffold is implanted subcutaneously, with the porous structure supporting persistent intravasation of host cells and vascularization.…”